PMC

SDF-1-induced survival is blocked by slit-2. Increasing concentrations of slit-2 (≥6 collapsing units) can block SDF-1-induced survival. p values were calculated by comparing each population with the untreated one using a two-tailed test with different variances.

Mice lacking CXCR4 have fewer RGCs. A, Confocal reconstruction of a representative 2 μm optical section from an E13.5 wild-type eye. B, Table comparing the number of islet-1-positive RGCs (see Materials and Methods) in wild-type and CXCR4 mutant eyes. The number of RGCs in mutant embryos is estimated to be ∼65% of those in wild-type littermates.

SDF-1 enhances the survival of embryonic mouse RGCs. After 24 (A; p = 0.001) or 72 (B; p = 0.005) hr in culture, an increased percentage of RGCs survive in the presence of 100 ng/ml SDF-1. p values were calculated by comparing each population with the untreated one using a two-tailed test with different variances. C, CXCR4 mRNA is expressed in the RGC cell layer of E13.5 mouse retina. D, At the same embryonic stage, SDF-1 mRNA is expressed in connective tissues surrounding the eye.

SDF-1 enhances survival and induces phosphorylation of MAP kinase and GSK3β in NT2N cells. A, SDF-1 100 ng/ml (p = 0.028) increases the number of NT2N cells after 24 hr in serum-free medium. p values were calculated by comparing each population with the untreated one using a two-tailed test with different variances. B, SDF-1 enhances phosphorylation of GSK3β and MAP kinase 44/42. The PKA inhibitor PKI at 20 μm blocks SDF-1-induced phosphorylation of GSK3β and MAP kinase. The MAP kinase inhibitor PD98059 at 20 μm also blocks the phosphorylation of both GSK3β and MAP kinase. The PKG antagonist KT5823 at 1 μm does not block SDF-1-induced phosphorylation of GSK3β and MAP kinase. C, Neither 100 ng/ml HxB-gp120 nor JRFL-gp120 affects GSK3β or MAP kinase phosphorylation on their own. HxB-gp120 but not JRFL-gp120 blocks SDF-1-induced phosphorylation of GSK3β and MAP kinase.

SDF-1 induces phosphorylation and translocation of CREB into the nucleus. E6 retinal neurons were cultured in defined minimal medium for 24 hr (A1–A3) and then exposed to 100 ng/ml SDF-1 (B1–B3), SDF-1 plus a 20 μm concentration of the CXCR4 antagonist AMD3100 (C1–C3), SDF-1 plus 100 ng/ml PTX (D1–D3), SDF-1 plus a 200 nm concentration of the PKA inhibitor PKI (E1–E3), or SDF-1 plus a 20 μm concentration of MAP kinase inhibitor PD98059 (F1–F3). After 30 min, the cultures were fixed and stained for islet-1 (A1–F1) (green) and phosphorylated CREB (A2–F2) (red). Merged images are shown in A3–F3. SDF-1 induces translocation of phosphorylated CREB into the nuclei of retinal neurons that is blocked by all three pharmacological agents.

SDF-1 reduces the percentage of TUNEL-positive RGCs. Dissociated E6 chick neural retinas were cultured for 48 hr, fixed, and processed for TUNEL staining (red) and islet-1 expression (green). A representative field is shown in phase-contrast optics (A) and in fluorescence (B). Some islet-1-expressing nuclei are also TUNEL-positive (arrows). C, The percentages of islet-1-positive cells with TUNEL staining were determined in the presence or the absence of 100 ng/ml SDF-1 (p = 0.002). The average percentages of TUNEL-positive RGCs are shown from four independent experiments. p values were calculated by comparing each population with the untreated one using a two-tailed test with different variances. Approximately threefold more TUNEL-positive RGCs were detected in the absence than in the presence of SDF-1.

SDF-1 promotes the survival of cultured embryonic chick RGCs, and its receptor CXCR4 is expressed in the embryonic retina. A, SDF-1 promotes the survival of RGCs in a dose-dependent manner. Shown are the percentages of surviving RGCs at 72 compared with 24 hr in the presence of 100 ng/ml selected chemokines or of 4 (p = 0.028), 20 (p = 0.008), or 100 ng/ml (p = 0.001) SDF-1. p values were calculated by comparing each population with the untreated one using a two-tailed test with different variances. B, Identification of RGCs in culture with anti-islet-1. C, Visualization of RGC neurons with an antibody to islet-1 in a cross section of an E6 chick embryo. The hash marks represent the ganglion cell layer. D, Visualization of CXCR4-expressing cells in the RGC layer of this same section by in situ hybridization. E, Merged image showing CXCR4 in all islet-1-positive cells.

SDF promotes the survival of cultured RGCs without promoting the translocation of TrkB to the cell surface. A, RGC survival is enhanced by 10 μm forskolin (p = 0.002) to the same degree as by 100 ng/ml SDF-1 (p = 0.001). The average percentages of surviving RGCs at 72 hr compared with 24 hr are shown for three independent experiments. p values were calculated by comparing each population with the untreated one using a two-tailed test with different variances. B, SDF-1-promoted survival is not affected by the src family inhibitor PP1, whereas BDNF survival is completely blocked. C–E, Forskolin but not SDF-1 induces the translocation of TrkB to the surface of RGCs. After 24 hr, cultures were left untreated (C1, C2) or treated for 30 min with 10 μm forskolin (D1,D2) or 100 ng/ml SDF-1 (E1,E2). All cultures were then stained live with anti-rabbit TrkB antibody. RGCs are visualized in green with anti-islet-1 (C1–E1), and surface TrkB is visualized in the same fields in red (C2–E2) (20×). Although both forskolin and SDF-1 promote the survival of RGCs, forskolin induces the translocation of TrkB to the surface of retinal cells, whereas SDF-1 does not.

Signaling pathways required for SDF-1-mediated RGC survival. The average number of RGCs per field 48 hr after plating is shown for each condition in four independent experiments. Each inhibitor was tested in the presence or absence of 100 ng/ml SDF-1. A, AMD3100 (20 μm), an antagonist of SDF-1 binding to CXCR4, does not affect RGC survival by itself but blocks the survival-enhancing effect of SDF-1. The G_i inhibitor PTX (100 ng/ml) does not affect RGC survival by itself but blocks the survival-enhancing effect of SDF-1. B, HxB-gp120 (100 ng/ml), anantagonist of SDF-1 binding to CXCR4, does not affect RGC survival by itself but blocks the survival-enhancing effect of SDF-1. JRFL-gp120 (100 ng/ml) does not antagonize SDF-1 binding and does not block its survival effect C, The cAMP antagonist Rp-cAMPS (20 μm) does not affect RGC survival by itself but blocks the survival-enhancing effect of SDF-1. The cGMP antagonist Rp-cGMPs (20 μm) has a lesser effect on SDF-1 activity than the cAMP antagonist. D, The PKA inhibitor PKI (200 nm) does not affect RGC survival by itself but blocks the survival-enhancing effect of SDF-1, whereas a 1 μm concentration of the PKG inhibitor KT5823 is less effective in blocking the effect of SDF-1. E, The survival effect of SDF-1 is also blocked by a 20 μm concentration of the MAP kinase inhibitor PD98059. In contrast, a 20 μm concentration of the PI-3 kinase inhibitor LY294002 does not reduce the effect of SDF-1. p values were calculated by comparing each population with the untreated one, and those with an asterisk were obtained comparing each population with the SDF-1-treated one using a two-tailed test with different variances.